HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Talc removed from 12th RoC

This article was originally published in The Rose Sheet

Executive Summary

Talc has been withdrawn from consideration for inclusion in National Toxicology Program's 12th Report on Carcinogens due to insufficient data on the substance, National Institutes of Health reports in an Oct. 18 Federal Register 1notice. Literature on the ingredient "provides an inadequate characterization of the actual materials under study to enable one to reach definitive conclusions concerning the specific substances responsible for the range of adverse health outcomes reported," NIH notes. Talc was listed last year as one of 21 nominations proposed for listing in the report, which is slated for publication in 2006 (2"The Rose Sheet" May 24, 2004, In Brief). Substance also was deferred from consideration in the 10th RoC due to insufficient evidence (3"The Rose Sheet" Dec. 18, 2000, p. 8). NTP is accepting comments on the decision until Nov. 17...

Related Content

RoC 12th edition
UVA, UVB "Reasonably Anticipated" To Be Human Carcinogens, NTP Rules



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts